Home › Compare › BJCHF vs ABBV
BJCHF yields 606.06% · ABBV yields 3.06%● Live data
📍 BJCHF pulled ahead of the other in Year 1
Combined, BJCHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BJCHF + ABBV for your $10,000?
Beijing Capital International Airport Company Limited engages in the aeronautical and non-aeronautical businesses at the Beijing Capital Airport in the People's Republic of China. The company's aeronautical business is involved in the provision of aircraft landings and take-offs; passenger service facilities; ground support services; and fire-fighting services for domestic and foreign air transportation enterprises. Its non-aeronautical business includes the franchise-based operation of ground handling agent services for domestic and foreign airliners; in-flight catering services; duty free and other retail shops in the terminals, as well as restaurants and other catering businesses in terminals; leasing advertising spaces inside and outside the terminals; and other businesses. The company's non-aeronautical business also comprises the leasing of properties in the terminals; provision of car parking services; and provision of ground handling facilities for ground handling agent companies. As of December 31, 2021, the company had 85 airliners operating fixed commercial flights at the Beijing Capital Airport, including 26 domestic airliners and 59 airliners from foreign countries; and operated 208 flight points linking with the Beijing Capital Airport, including 133 domestic flight points and 75 international flight points. The company was incorporated in 1999 and is based in Beijing, the People's Republic of China. Beijing Capital International Airport Company Limited is a subsidiary of Capital Airports Holding Limited.
Full BJCHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.